---
title: "Morgan Stanley Sticks to Its Buy Rating for RegenXBio (RGNX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286567070.md"
description: "Morgan Stanley analyst Judah Frommer has reaffirmed a Buy rating for RegenXBio (RGNX) with a price target of $16.00. Frommer, a 2-star analyst, has a 52.86% success rate. Stifel Nicolaus also issued a Buy rating for RegenXBio, while Goldman Sachs maintained a Hold rating."
datetime: "2026-05-15T12:38:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286567070.md)
  - [en](https://longbridge.com/en/news/286567070.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286567070.md)
---

# Morgan Stanley Sticks to Its Buy Rating for RegenXBio (RGNX)

In a report released today, Judah Frommer from Morgan Stanley maintained a Buy rating on RegenXBio, with a price target of $16.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Frommer is a 2-star analyst with an average return of 0.7% and a 52.86% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Evommune, Inc., Lakefront Biotherapeutics, and COMPASS Pathways.

In addition to Morgan Stanley, RegenXBio also received a Buy from Stifel Nicolaus’s Annabel Samimy in a report issued today. However, yesterday, Goldman Sachs maintained a Hold rating on RegenXBio (NASDAQ: RGNX).

### Related Stocks

- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [EVMN.US](https://longbridge.com/en/quote/EVMN.US.md)
- [LKFT.US](https://longbridge.com/en/quote/LKFT.US.md)
- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | RGNX Stock News](https://longbridge.com/en/news/286403513.md)
- [REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights | RGNX Stock News](https://longbridge.com/en/news/286405286.md)
- [RegenXBio Advances RGX-202 With Positive Phase III Results](https://longbridge.com/en/news/286412399.md)
- [16:05 ETREGENXBIO to Participate in Upcoming Investor Conferences](https://longbridge.com/en/news/286813324.md)
- [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)